Table 2.
Injections and planned/observed treatment regimen (FAS)
| Treatment-naïve (n = 181) |
Previously treated (n = 77) |
Overall (n = 258) |
|
|---|---|---|---|
| Planned treatment regimen | |||
| T&E from initial treatment | 29 (16.0) | 10 (13.0) | 39 (15.1) |
| 5 initial monthly injections followed by T&E | 39 (21.6) | 18 (23.4) | 57 (22.1) |
| 5 initial monthly injections followed by injections every other month | 4 (2.2) | 0 | 4 (1.6) |
| Treat until dry followed by T&E | 20 (11.1) | 11 (14.3) | 31 (12.0) |
| Treat until dry followed by PRN | 42 (23.2) | 13 (16.9) | 55 (21.3) |
| PRN from initial treatment | 28 (15.5) | 19 (24.7) | 47 (18.2) |
| Other | 19 (10.5) | 6 (7.8) | 25 (9.7) |
| Reported treatment regimena | |||
| T&E | 25 (13.8) | 10 (13.0) | 35 (13.6) |
| 5 initial monthly injections followed by T&E | 13 (7.2) | 6 (7.8) | 19 (7.4) |
| Treat until dry followed by T&E | 17 (9.4) | 10 (13.0) | 27 (10.5) |
| Treat until dry followed by PRN | 60 (33.2) | 11 (14.3) | 71 (27.5) |
| PRN from initial treatment | 29 (16.0) | 21 (27.3) | 50 (19.4) |
| No initial treatment | 10 (5.5) | 7 (9.1) | 17 (6.6) |
| Other | 27 (14.9) | 12 (15.6) | 39 (15.1) |
| Mean IVT-AFL injections by Month 6 (mean ± SD) | 2.9 ± 1.2 | 3.2 ± 1.6 | 3.0 ± 1.3 |
| Mean IVT-AFL injections by Month 12 (mean ± SD) | 3.7 ± 1.8 | 4.0 ± 2.2 | 3.8 ± 1.9 |
| ≥ 5 injections within 6 months | 13 (7.2) | 19 (24.7) | 32 (12.4) |
| ≥ 8 injections within 12 months | 7 (3.9) | 7 (9.1) | 14 (5.4) |
Data are n (%), unless otherwise stated
FAS full analysis set, IVT-AFL intravitreal aflibercept, PRN pro re nata, SD standard deviation, T&E treat and extend
aAs reported by the investigator(s)